Radiographic progression can still occur in individual patients with low or moderate disease activity in the current treat-to-target paradigm: real-world data from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry

被引:18
|
作者
ten Klooster, Peter M. [1 ,2 ,3 ]
Versteeg, Letty G. A. [2 ,4 ]
Oude Voshaar, Martijn A. H. [1 ,2 ]
de la Torre, Inmaculada [5 ]
De Leonardis, Francesco [5 ]
Fakhouri, Walid [6 ]
Zaremba-Pechmann, Liliana [5 ]
van de Laar, Mart [1 ,2 ,4 ]
机构
[1] Transparency Healthcare, Hengelo, Netherlands
[2] Univ Twente, Arthrit Ctr Twente, Enschede, Netherlands
[3] Univ Twente, Dept Psychol Hlth & Technol, POB 217, NL-7500 AE Enschede, Netherlands
[4] Med Spectrum Twente, Arthrit Ctr Twente, Enschede, Netherlands
[5] Eli Lilly & Co, Indianapolis, IN 46285 USA
[6] Eli Lilly & Co, Windlesham, Surrey, England
关键词
Rheumatoid arthritis; Treat-to-target; Disease activity; Radiographic damage; Real-world data; C-REACTIVE PROTEIN; ACUTE-PHASE RESPONSE; JOINT DAMAGE; RADIOLOGICAL PROGRESSION; PLUS METHOTREXATE; ACTIVITY SCORES; INFLAMMATION; STRATEGY; DESTRUCTION; REMISSION;
D O I
10.1186/s13075-019-2030-8
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BackgroundThe aim of this retrospective study was to examine the longitudinal association between disease activity and radiographic damage in a cohort of patients with early RA (symptom onset <1year) treated according to treat-to-target (T2T) therapy.MethodsBaseline to 3-year follow-up data were used from patients included in the DREAM remission induction cohort. Patients received protocolized T2T treatment, aimed at 28-joint disease activity score-erythrocyte sedimentation rate (DAS28-ESR) remission. Disease activity (DAS28-ESR and C-reactive protein, CRP) were assessed at least every 3months; X-rays of the hand and feet at inclusion, 6months, and 1, 2, and 3years were scored using modified Sharp/van der Heijde scoring (SHS). Between and within-person associations between time-integrated disease activity and radiographic progression over time were examined.ResultsA subset of 229 out of 534 included patients were available for analysis. At the between-patient level, time-integrated DAS28-ESR scores were not significantly correlated with progression at the 6month and 2-year follow-up and only weakly at the 1-year (Pearson's correlation coefficient r=0.17, P<0.05) and 3-year follow-up (r=0.21, P<0.05). Individual slopes of the relationship between DAS28-ESR and progression scores in each time interval were significantly correlated over time and the slope of the first 6months was moderately associated with this slope at later time points (r between 0.39 and 0.59; P values <0.001). Between 15.9 to 22.7% and 16.7 to 38.5% of patients with low and moderate time-integrated disease activity, respectively, experienced relevant (Delta SHS >= 3) radiographic progression at the different time intervals. Analyses using CRP showed similar results.ConclusionsIn early RA patients treated according to T2T, radiographic progression appears to be an individually determined disease process, driven by factors other than consistent high disease activity. For individual patients, the intra-patient relation between disease activity and cumulative radiographic damage during the first 6months is a good indicator for this relation in later years.Trial registrationNetherlands Trial Register NTR578, 12 January 2006.
引用
收藏
页数:10
相关论文
共 20 条
  • [1] Radiographic progression can still occur in individual patients with low or moderate disease activity in the current treat-to-target paradigm: real-world data from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry
    Peter M. ten Klooster
    Letty G. A. Versteeg
    Martijn A. H. Oude Voshaar
    Inmaculada de la Torre
    Francesco De Leonardis
    Walid Fakhouri
    Liliana Zaremba-Pechmann
    Mart van de Laar
    [J]. Arthritis Research & Therapy, 21
  • [2] Association between Disease Activity and Radiographic Progression in the Current Treat-to-Target Paradigm of Rheumatoid Arthritis: Real World Data from the Dutch Rheumatoid Arthritis Monitoring (DREAM) Registry
    ten Klooster, Peter M.
    Steunebrink, Laura M. M.
    Versteeg, Letty
    de la Torre, Inmaculada
    de Leonardis, Francesco
    Fakhouri, Walid
    Zaremba-Pechmann, Liliana
    van de Laar, Mart
    [J]. ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [3] Monitoring of rheumatoid arthritis disease activity in individual patients: still a hurdle when implementing the treat-to-target principle in daily clinical practice Monitoring disease activity in individual RA patients
    Jacobs, Johannes W. G.
    Ten Cate, David F.
    van Laar, Jacob M.
    [J]. RHEUMATOLOGY, 2015, 54 (06) : 959 - 961
  • [4] Treat-to-target strategy in patients with rheumatoid arthritis: Audit adherence from real world clinical data
    Andreu, Jose-Luis
    Auxiliadora Martin, Maria
    Corominas, Hector
    Javier Perez-Venegas, Jose
    Andres Roman-Ivorra, Jose
    Sanchez-Alonso, Fernando
    Gil de Miguel, Angel
    [J]. REUMATOLOGIA CLINICA, 2021, 17 (04): : 212 - 214
  • [5] Real-world treat-to-target skin clearance with risankizumab in patients with moderate to severe psoriasis from the CorEvitas Psoriasis Registry
    Armstrong, April W.
    Ferris, Laura K.
    Duffin, Kristina Callis
    Janak, Jud
    Sima, Adam
    Eckmann, Thomas
    Patel, Manish
    Photowala, Huzefa
    Garg, Vishvas
    Strober, Bruce
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB200 - AB200
  • [6] Radiographic progression in early rheumatoid arthritis patients following initial combination versus step-up treat-to-target therapy in daily clinical practice: Results from the DREAM registry
    Steunebrink L.M.M.
    Versteeg L.G.A.
    Vonkeman H.E.
    ten Klooster P.M.
    Hoekstra M.
    van de Laar M.A.F.J.
    [J]. BMC Rheumatology, 2 (1)
  • [7] Adherence to a Treat-To-Target Strategy is Key to Attainment of Sustained Remission in Rheumatoid Arthritis: Data from the Real-world Practice BIODAM Cohort
    Homik, Joanne
    Larche, Maggie
    Boire, Gilles
    Barnabe, Cheryl
    Rahman, Proton
    Hitchon, Carol
    Hutchings, Edna
    Dadashova, Rana
    Paschke, Joel
    Maksymowych, Walter
    [J]. JOURNAL OF RHEUMATOLOGY, 2016, 43 (06) : 1223 - 1224
  • [8] First Report of Golimumab Real-World Effectiveness in Low/Moderate and High Disease Activity in Patients with Rheumatoid Arthritis
    Bensen, William
    Choquette, Denis
    Zummer, Michel
    Sholter, Dalton
    Chow, Andrew
    Dixit, Sanjay
    Sampalis, John
    Nantel, Francois
    Shawi, May
    Lehman, Allen
    Otawa, Susan
    [J]. JOURNAL OF RHEUMATOLOGY, 2013, 40 (06) : 1021 - 1021
  • [9] Long Term Real-World Treat-to-Target Skin Clearance and Maintenance of Response with Risankizumab in Patients with Moderate to Severe Psoriasis From the CorEvitas Psoriasis Registry
    Armstrong, April W.
    Ferris, Laura K.
    Duffin, Kristina Callis
    Janak, Jud C.
    Sima, Adam P.
    Eckmann, Thomas
    Photowala, Huzefa
    Patel, Manish
    Garg, Vishvas
    Strober, Bruce E.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB62 - AB62
  • [10] Do Patients With Moderate or High Disease Activity Escalate Rheumatoid Arthritis Therapy According to Treat-to-Target Principles? Results From the Rheumatology Informatics System for Effectiveness Registry of the American College of Rheumatology
    Yun, Huifeng
    Chen, Lang
    Xie, Fenglong
    Patel, Himanshu
    Boytsov, Natalie
    Zhang, Xiang
    Curtis, Jeffrey R.
    [J]. ARTHRITIS CARE & RESEARCH, 2020, 72 (02) : 166 - 175